AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Dihydroquinazoline-Derived Inhibitors for Alzheimer's Disease Treatment

Summary

Researchers at Purdue University have developed novel compounds that inhibit beta-secretase for Alzheimer's treatment. By focusing on a known dihydroquinazoline scaffold, a series of novel dihydroquinazoline derivatives were synthesized and evaluated. Several compounds in this series were shown to exhibit better beta-secretase cellular inhibitory activity compared to current compounds reported in literature. These compounds show increased potency, improved aqueous solubility, increased metabolic stability, and improved oral bioavailability.

Technology Benefits

Improved beta-secretase cellular inhibitionIncreased metabolic stability

Technology Application

Medical/HealthcarePharmaceutical Industry

Detailed Technology Description

Arun GhoshGhosh GroupPurdue Chemistry

Countries

United States

Application No.

8,394,807

Country/Region

USA

For more information, please click Here